N-甲基-3-氯吡啶-4-甲酰胺 | 1021464-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-甲基-3-氯吡啶-4-甲酰胺
• 英文名称: N-methyl-3-chloropyridine-4-carboxamide
• 英文别名: 3-chloro-N-methylisonicotinamide；3-chloro-N-methylpyridine-4-carboxamide
• CAS: 1021464-02-7
• 化学式: C₇H₇ClN₂O
• 分子量: 170.598
• InChiKey: UOEQDNBHTJLQRS-UHFFFAOYSA-N

物化性质

• 熔点：
  76-77 °C
• 沸点：
  315.5±27.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-甲基-3-氯吡啶-4-甲酰胺 在 N,N-二甲基甲酰胺 氯化亚砜 作用下， 反应 0.5h， 生成 3-chloro-N-methylisonicotinamide
  参考文献：
  名称：

  TRIAZOLE DERIVATIVE OR SALT THEREOF

  摘要：

  公开号：

  EP2298747B1
• 作为产物：
  描述：

  N-甲基-4-吡啶甲酰胺 在 六氯乙烷 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以44%的产率得到N-甲基-3-氯吡啶-4-甲酰胺
  参考文献：
  名称：

  Deprotonation of pyridine carboxamides using lithium magnesiates bases

  摘要：

  Regioselective deprotonation of N-methyl- and tert-butylpyridine carboxamides using lithium magnesiates bases was achieved at room temperature avoiding nucleophilic addition on the pyridine molecule and auto-condensation of the arylmetal intermediates on the amide group was described. The hydrogen-magnesium exchange was evidenced using H-1 NMR spectroscopy at room temperature and the reactivity of the lithium 2- 3- and 4-carboxamidopyridinylmagnesiates complexes towards electrophiles and in cross-coupling reactions was studied. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.01.064

文献信息

• CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE
  申请人：Ng Simon C.

  公开号：US20100130490A1

  公开（公告）日：2010-05-27

  Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

  本发明公开了苯并噁唑和苯并噻唑化合物及其氧化物、酯、前药、溶剂化物和药学上可接受的盐。本发明还公开了该化合物的组合物，其可以单独使用或与至少一种额外治疗剂联合使用，并与药学上可接受的载体一起使用。该实施例可用于抑制细胞增殖，抑制肿瘤的生长和/或代谢，治疗或预防癌症，治疗或预防退变性骨疾病，如类风湿性关节炎，并/或抑制分子，如CSF 1R。
• CSF-1R inhibitors, compositions, and methods of use
  申请人：Novartis AG

  公开号：US08293769B2

  公开（公告）日：2012-10-23

  Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

  本文介绍了苯并噁唑和苯并噻唑化合物及其氧化物、酯类、前药、溶剂和药物可接受的盐。该化合物的组合物，可以单独使用或与至少一种其他治疗剂合用，并且可以与药物可接受的载体一起使用。该化合物的用途包括抑制细胞增殖，抑制肿瘤的生长和/或代谢，治疗或预防癌症，治疗或预防类风湿性关节炎等骨骼退化性疾病，以及抑制CSF 1R等分子。
• WO2008/144062
  申请人：——

  公开号：——

  公开（公告）日：——
• CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE
  申请人：Novartis AG

  公开号：EP2152700A1

  公开（公告）日：2010-02-17
• US8293769B2
  申请人：——

  公开号：US8293769B2

  公开（公告）日：2012-10-23